CITY OF INDUSTRY, Calif.--(BUSINESS WIRE)--June 2, 2006--AXM Pharma, Inc. (AMEX: AXJ - News), a manufacturer of proprietary and generic pharmaceutical and nutraceutical products for the Chinese and other Asian markets, announced today that it has received a letter from the Staff of the American Stock Exchange (“Amex”) stating that a Listing Qualifications Panel (the “Panel”) has reviewed and approved the Amex Staff’s determination to delist the Company’s common stock. Accordingly, Amex intends to suspend trading in the Company’s common stock as soon as practicable and will proceed with the filing of an application with the Securities and Exchange Commission (“SEC”) to strike the Company’s common stock from listing on the Amex.
